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Abstract
Background: Several gene sets for prediction of breast cancer survival have been derived from whole-genome mRNA
expression profiles. Here, we develop a statistical framework to explore whether combination of the information from such
sets may improve prediction of recurrence and breast cancer specific death in early-stage breast cancers. Microarray data
from two clinically similar cohorts of breast cancer patients are used as training (n=123) and test set (n=81), respectively.
Gene sets from eleven previously published gene signatures are included in the study.
Principal Findings: To investigate the relationship between breast cancer survival and gene expression on a particular gene
set, a Cox proportional hazards model is applied using partial likelihood regression with an L2 penalty to avoid overfitting
and using cross-validation to determine the penalty weight. The fitted models are applied to an independent test set to
obtain a predicted risk for each individual and each gene set. Hierarchical clustering of the test individuals on the basis of
the vector of predicted risks results in two clusters with distinct clinical characteristics in terms of the distribution of
molecular subtypes, ER, PR status, TP53 mutation status and histological grade category, and associated with significantly
different survival probabilities (recurrence: p=0.005; breast cancer death: p=0.014). Finally, principal components analysis
of the gene signatures is used to derive combined predictors used to fit a new Cox model. This model classifies test
individuals into two risk groups with distinct survival characteristics (recurrence: p=0.003; breast cancer death: p=0.001).
The latter classifier outperforms all the individual gene signatures, as well as Cox models based on traditional clinical
parameters and the Adjuvant! Online for survival prediction.
Conclusion: Combining the predictive strength of multiple gene signatures improves prediction of breast cancer survival.
The presented methodology is broadly applicable to breast cancer risk assessment using any new identified gene set.
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Introduction
Cancer is a complex disease characterized by a number of genetic
and epigenetic abnormalities.Patients associated with similar clinical
and pathological parameters may have very different tumor profiles
at the molecular level and may respond differently to treatment
[1,2,3,4]. Genome-wide expression profiling of tumors has become
an important tool to identify gene sets and gene signatures that can
be used to predict clinical endpoints, such as survival and therapy
response[1,2,3,5,6,7,8,9,10,11,12].A numberoftumorclassification
algorithms based on gene expression profiles have been proposed,
using clinical data or known biological class labels to build predictive
models for outcome: e.g. the 70-gene signature MammaPrintH [3],
the 76-gene signature of Wang et al. [8] and the Genomic Grade
Index [4]. Several classification methods also utilize unsupervised
methods to discover biological subgroups [1,5,9].
Published gene signatures that are predictive of clinical outcome
in breast cancer are partly or completely based on different genes.
Nevertheless, their predictions are often in good concordance in
terms of assigning new patient samples into groups of poor and
good outcome [13,14]. This indicates that some common
biological processes overlap across those gene signatures [14,15],
but the reported gene signatures are likely to capture various
biological aspects of breast cancer. Hence, by combining
information from multiple gene signatures, one would potentially
increase the prediction power and bring out an overall picture of
this disease.
We therefore aim to develop an analytical framework that
allows us to utilize the combined strength from individual gene
signatures. Such a framework and the resulting model will be
broadly applicable for survival prediction across heterogeneous
tumor groups capturing a broad spectrum of biological aspects.
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recalibration on new datasets. As a consequence, the original gene
signatures will not always be maintained and used as originally
intended. In this paper, the aim is not to compare or condition on
the original gene signatures per se, but rather to focus on the genes
themselves. Thus we rely only on the gene sets on which the gene
signatures are based, and fit survival models based on these gene
sets without depending on the quantitative specifics of the
published gene signatures. In doing so, we are able to utilize
what is arguably the most critical piece of information from the
gene signatures, and analytically most challenging to derive:
shortlists of genes related to breast cancer survival. It should be
emphasized that the main aim of our study is to present a method
for explorative analyses and for seeding gene selection algorithms
with prior known gene sets, rather than a claimed method for
producing optimized gene signatures competing with published
counterparts.
We use the gene sets of eleven published gene signatures to
analyze breast cancer survival and relapse (Table 1). We aim to
build survival predictors on a common data set to achieve a fair
comparison of the gene sets. For each gene set, we fit survival
models to one dataset and apply them to another to obtain
predictions of cancer relapse and death, resulting in a predictive
index (PI) per patient. We then combine the PIs obtained for a
patient by extracting a common signal using the first principal
component, in order to improve the predictions obtained by each
gene set separately. We illustrate the capacity of the proposed
framework to lead to improved survival prediction. A flowchart of
the analysis is shown in Figure 1; see specific sections under Results
for a detailed explanation of the different parts of the figure.
Results
Cross-platform gene mapping
Using the gene mapping procedure described in Methods, we
were able to identify and map at least 80% of the genes from each
of the originally published gene sets to the Stanford 43k cDNA
array. Table 2 summarizes the number of genes mapped to the
training set (MicMa [11]) and test set (Ull [16]). The number of
genes that overlap between the different gene sets is shown in
Table 3. The percentage of overlap ranges from 0 to 25%
(between Robust and Grade) with a median overlap of 0.57%.
Penalized Cox regression
For each gene set, a Cox model was used to relate time to
systemic relapse to gene expression (see the second last section in
Results for analysis using breast cancer specific death as the
clinical endpoint). A weight is thus assigned to each gene and a
risk score (or prognostic index, PI) is found for each individual by
adding together the weighted gene expressions. Due to the large
number of covariates, ranging from 15 genes (RS; [6]) up to 561
genes (WR; [5]), we estimated a penalized partial likelihood,
where the penalty is proportional to the Euclidean (L2) norm of
the parameter vector. This has the effect of avoid over-fitting by
reducing the variance of the estimator, at the cost of introducing
a bias. A penalty parameter l controls the trade-off between the
goodness of fit (imposed by the partial likelihood) and low
variance (imposed by the penalty term). As lR0t h es o l u t i o n
approaches that of ordinary Cox regression, while as lR‘ the
solution approaches that of a constant estimator that does not
depend on the expression of any gene. In practice, a good choice
for l has to be determined empirically, and for this purpose we
applied leave-one-out cross-validation (LOOCV) [17]. The
cross-validation curves obtained for each of the gene sets are
shown in Figure S1, and the l that maximizes the cross-
validation function can be found in Table 4. For gene sets SD
and LM, the cross-validation function did not have a maximum
in the search range resulting in a null model that has no
covariates.
Prediction of survival with the prognostic index
Adding together the weighted gene expressions for a particular
gene set, each patient in the test set was assigned a Prognostic
Index (PI). The distributions of the PIs are shown in Figure 2A;
observe that some gene sets discriminate the patients on a wider
range of risk scores than others. The deviance, an indicator of the
models’ goodness of fit, was calculated for each gene set. Table 4
shows the difference in deviance (DD) between the fitted models
and a null model with no genes. The magnitude of DD indicated
the prediction power gained by a gene-set predictor. For gene sets
with positive DD, the corresponding gene-set models were likely
to perform poorly in prediction. Since no optimal l was found for
gene set SD and LM, the corresponding DD was 0. The standard
deviation of the empirical PI distributions can be found in
Table 4.
Table 1. Published gene sets included in the analysis.
Coding Full name Platform
RS 16-gene-recurrence-score predictor [6] Oncotype DX assay
SD 26-gene stroma-derived prognostic predictor [21] Agilent Human oligo microarrays
LM 54-lung-metastasis-gene signature [7] Affymetrix GeneChips
AMST 70-gene predictor [3] Agilent Human oligo microarrays
ROT 76-gene predictor [8] Affymetrix GeneChips
Grade 97- histologic-grade-associated markers [4] Affymetrix GeneChips
Robust 127-gene classifier [31] Affymetrix GeneChips
Hypoxia 168-hypoxia-gene signature [9] Stanford 43k cDNA array
Stem 186-invasiveness-gene signature [10] Affymetrix GeneChips
Intrinsic 306-intrinsic/UNC gene list [12] Agilent Human oligo microarrays
WR 512 wound response gene list [5] Stanford 43k cDNA array
doi:10.1371/journal.pone.0017845.t001
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The predicted PIs for the test patients by each of the individual gene
sets in our study were stacked into a PI matrix where rows indicate the
identity of the gene set, columns indicate the identity of the patient in
the test set and each cell contains the predicted PI risk score for relapse
of a specific patient by a specific gene set (Figure 1B). Hierarchical
clustering of the patients based on the PI matrix revealed two risk
groups with distinct clinical characteristics (Figure 3A) and associated
with significantly different survival probabilities (Figure 3B: Logrank
test: x
2=7.8,df=1,p=0.005). This is in line with the findings from
the results on the training set (Figure S2; see Methods S1 Part IV for
calculation of the estimated PIs on the training set and Part V for a
brief discussion on the results). A control sample included in the Ull set
(DNR_N_100; marked in green in Figure 3A, see Materials and
Methods) was correctly classified to the low risk group. Clinical and
molecular characteristics for each of the two clusters are summarized
in Table 5. For the 77 patients in the test set, the low risk group
consisted of44 patients;14of them had developed systemicrecurrence
within the follow-up time period. Furthermore, 29 out of 38 luminal A
tumors (76%), 5 out of 13 basal-like tumors (39%), 33 out of 45 ER
positive tumors (73%), 32 out 51 PR positive tumors (63%), 2 out of 20
TP53 mutated tumors (10%) and all 6 Grade 1 tumors (100%)
belonged to this group. The high risk group consisted of 33 patients of
whom 20 experienced relapse within the follow-up time period with
53.9 month median survival time. Moreover, 9 out of 38 Luminal A
tumors (24%); 8 out of 13 basal tumors (61%) and almost all TP53
mutated tumors (18/20, 90%) belonged to the high risk group.
Prediction by individual gene sets
The concordance structure for survival prediction among the
studied gene sets is shown in the heatmap of the Spearman
correlation matrix on continuous PI scales (Figure 4A). The gene
sets SD and LM were left out since no optimal tuning parameter l
could be found. It should be noted that Hypoxia showed weak
correlations with other gene sets, whereas Robust, Grade and RS
were highly correlated.
Figure 1. Flowchart of the analysis. (A) Construction of the gene-set predictor/gene signature for risk prediction. Input: A set of genes of interest
(gene 1,… ,m) which can be traced by the corresponding colors through out the diagram; gene expression data for training cohort and test cohort
with genes placed in the rows and patients in the columns. Step 1. Gene identity mapping and extract expression matrix. Step 2. With available status
of observing an event for the patients on the training set, a Cox model with L2 penalty is used to model the relationship of survival probability and
gene expression pattern of the gene set. The coefficients or ‘‘gene weights’’ (b1,… ,bm) associated with individual genes are estimated from the Cox-
ridge model. Size of the bubble in the gene weights matrix reflects the importance of the corresponding gene for survival prediction. Step 3.A
Prognostic Index (PI), the predicted risk score for a test patient i (i=1, …, n) is calculated by the sum of weighted gene expression from test patient i
using the estimated gene weights from step2. (B) Integration of multiple gene signatures by dimension reduction. Input multiple gene sets of
interest together with their gene expression data. Module 1: For jth gene set (j=1,…, R), the procedure described in panel A is used to predict a risk
score PI for individual test patient. The resulting PI matrix is positioned in R by n dimension representing the risk prediction of the n test patients by
each of the R gene sets. Module 2: Integrate predictions from multiple gene signatures by dimension reduction using principal components analysis
(PCA). Module 3: Dichotomize the risk scores on PC1 by median (higher than median indicates high risk) resulting in two predicted risk groups for
survival outcome.
doi:10.1371/journal.pone.0017845.g001
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positive PI score were assigned to the high risk group and the
remaining patients to the low risk group. The survival probabilities
associated with the dichotomized risk groups were assessed by the
logrank test. Kaplan-Meier plots for the predicted groups are shown
in Figure 5 for each of the individual gene sets. Three gene sets were
found to be significant: Grade (p=0.012), Robust (p=0.02) and RS
(p=0.027). Previously, we observed that predictions by these three
gene sets were highly correlated, which explains their similar
performances on the dichotomous scale of PI. In addition, two gene
sets were borderline significant: ROT (p=0.058) and WR (p=0.077).
Using principal components analysis to obtain a
combined risk predictor
The concordance structure among the studied gene sets for
survival prediction (Figure 3A and Figure 4A) indicated that the
main signal related to survival should be well captured by a lower
dimensional representation of the PI vector associated with a
patient. Consider the PI matrix (rows indicate gene sets and
columns indicate patients) consisting of the predicted PIs of the test
patients from the 9 converged gene sets in the model training. We
used principal components analysis to derive linear combinations
of the original nine-dimensional PI vectors that captured most of
the variability of the PIs. Figure 6A shows a scatter plot of the
combined risk prediction scores for the test patients on the first two
principal components. The first principal component (PC1)
captured 64% of the total variation and a total of 76% cumulative
proportion of variation was captured by the first two components
(Table S1). An increasing proportion of relapses were observed at
the higher end of PC1. We created two classes by dividing the PC1
risk scores at the median value (20.45); thus any patient with a
PC1 risk score larger than 20.45 was considered to be a high-risk
patient, and any patient with a PC1 risk score less than or equal to
20.45 was considered to be a low-risk patient. The two risk groups
were associated with significantly different survival probabilities
(Figure 6B, logrank test p=0.003).
Table 2. Acronyms for original gene sets and coverage on
training & test set.
Gene set Mapped genes # Coverage %
RS 15 15/16=94%
SD 22 22/26=85%
LM 48 48/54=89%
AMST 57 57/70=81%
ROT 66 66/76=87%
Grade 111 111/128
1=87%
Robust 114 114/127=90%
Hypoxia 168 168/168=100%
Stem 161 161/186=87%
Intrinsic 290 290/306=95%
WR 561 561/573
{ =98%
1128 Affymetrix probe IDs were used instead of 97 gene symbols.
{573 image clone IDs were used instead of 512 genes.
doi:10.1371/journal.pone.0017845.t002
Table 3. Number of overlapping genes between gene sets.
RS SD LM AMST ROT Grade Robust Hypoxia Stem Intrinsic WR
R S 0010320151
S D 0 010011001
L M 00 00001075
A M S T 110 0771023
ROT 0 0 0 0
1 721043
G r a d e 30077 4 5 001 1 1 2
Robust 2 1 0 7 2 45 2 4 11 10
H y p o x i a0111102 431 2
Stem 1 0 0 0 0 0 4 4 5 7
Intrinsic 5 0 7 2 4 11 11 3 5 19
W R 115331 2 1 0 1 2 71 9
1There was 1 gene overlapping between ROT & AMST according to the previous report [15]: CCNE2 (GenBankID NM_004702). However, in the newer version of the NCBI
database: ‘‘NM_004702.2 was permanently suppressed because the transcript has insufficient support and is a nonsense-mediated mRNA decay (NMD) candidate.’’
(http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=17318566. Accessed on Mar. 18, 2009).
doi:10.1371/journal.pone.0017845.t003
Table 4. Individual gene set prediction characteristics
(optimal l by LOOCV in model building, change in deviance
on test set, standard deviation for PIs).
Prediction characteristics statistic
Gene Set lopt D Deviance Sd (PI)
RS 338 -1.4 0.109
SD - 0 0
LM - 0 0
AMST 227 0.3 0.195
ROT 1029 0.1 0.095
Grade 3580 -2.12 0.078
Robust 1705 -2.57 0.121
Hypoxia 392 -0.71 0.245
Stem 3623 -0.25 0.044
Intrinsic 1576 -0.88 0.137
WR 11261 -0.37 0.037
doi:10.1371/journal.pone.0017845.t004
Combining Gene Signatures in Breast Cancer
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17845Univariate comparison of predictors
We performed univariate analysis for individual gene-set
predictors as well as for clinical parameters including tumor size
(pT1, pT2 and pT3-pT4), TP53 mutation status, stage (1–4), node
status (pN0, pN1, pN2-pN3 and pNx), ER status (positive versus
negative), histological grade (1–3) and the Adjuvant! Online model
(AOL), respectively. AOL is an established on-line breast cancer
survival predictor; it calculates a 10-year survival probability based
on the patient’s age, tumor size, tumor grade, oestrogen-receptor
status, and nodal status. Patients were assigned to the low risk
group if their 10-year mortality risk was lower than 10% as
predicted by Adjuvant! Online software. The dichotomized PI
scores (positive scores indicate high risk and nonpositive scores
indicate low risk) for the gene-set predictors were used in the
univariate Cox model. The performance comparisons by using the
likelihood ratio test, the deviance, the proportion of variation explained
(PVE), the concordance index (C-index) and the Hazard Ratio (HR) are
summarized in Table 6, Figure 7 and Table S2 for the combined-
Figure 2. Boxplot of predicted PIs on test data. (A) Systemic recurrence: The figure shows that the predicted PIs across all the studied gene sets
were roughly centered around 0, resulting from the standardization procedure of the expression matrix on both training and test set for individual
gene set in the model building stage. The standard deviations of PIs for individual gene set are following: RS: 0.109; SD: 0; LM: 0; AMST: 0.195; ROT:
0.095; Grade: 0.078; Robust: 0.121; Hypoxia: 0.245; Stem: 0.044; Intrinsic: 0.137; WR: 0.037. Due to lack of convergence, the predicted PIs by gene set
SD and LM was calculated by setting tuning parameter l, at a large value. (B) Breast cancer specific death (BC specific death): Boxplot of predicted PIs
on test set. Gene set LM failed to converge in the model training.
doi:10.1371/journal.pone.0017845.g002
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included predictors.
The combined-PI risk predictor was competitive in all the
tested measurements. It showed the most significant effect on
survival (p=0.003) and it was associated with the second highest
C-index score (C=0.75) following TP53 mutation status
(C=0.76). The information carried by the Deviance and PVE
is highly consistent (Figure 7A). The combined-PI risk predictor
Figure 3. Hierarchical clustering of predicted PIs on test set and Kaplan-Meier analysis of the clusters. Results for systemic recurrence
are in (A–B); for BC specific death in (C–D). In heatmaps (A, C), rows are notations for the gene sets. Columns are annotation for the patients; data
outside of 1% quantile were trimmed. ‘‘Average’’ linkage based on Spearman correlation was used to construct the dendrograms. Figure A and C
share legends for the clinical parameters. (A) Heatmap of predicted PIs on the test set for systemic recurrence from each gene sets. Two risk groups
were observed from the hierarchical clustering; cluster I and cluster II. The control sample in Ull DNR_N_100, marked by green, was classified in the
cluster associated with a lower risk (cluster II). (B) The Kaplan-Meier curves for the two clusters. A significant separation between the two groups was
observed (x
2=7.8, df=1, p=0.005). (C) Heatmap of predicted PIs on the test set for BC specific death from each gene sets. Two risk groups were
observed from the hierarchical clustering; cluster I and cluster II. The control sample in Ull DNR_N_100, marked by green, was classified in the cluster
associated with a lower risk (cluster I). (D) A significant separation between the two Kaplan-Meier curves associated with the clusters was observed
(x
2=5.996, df=1, p=0.014).
doi:10.1371/journal.pone.0017845.g003
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(9.36), indicating good fit of the model. Furthermore, the
predictor alone explained 10.6% of the variability as indicated
by PVE, following tumor size (11.7%) and stage (11.1%); see
Table 6. The high risk group assigned by the combined-PI risk
predictor had a hazard rate of 2.82 (95% CI 1.37—5.80;
Figure 7B; Table S2) times higher than the low risk group.
Among all the tested predictors, TP53 mutation status was the
only factor that gave a slightly higher HR (2.87 with 95% CI
1.42—5.83; Figure 7B; Table S2).
The proportional hazards assumption, where the hazard ratios
over time are constant, held in all the reported univariate Cox
models, expect for ER status (p=0.009; Table S2).
Multivariate comparison of predictors
A multivariate Cox model was used to simultaneously assess
the combined-PI risk predictor and the traditional clinical and
molecular parameters that yielded significant results in the
univariate comparison (TP53 mutation status and tumor size).
Due to the known association between ER status and survival, we
included ER status as stratification variable and each stratum is
permitted to have a different baseline hazard function while the
coefficients of the remaining covariates are assumed to be
constant across the strata. We observed a high correlation
between TP53 mutation status and the combined-PI risk
predictor (odds ratio 15.0 (95% CI 3.1—145.7), Fisher’s Exact
test p,0.001). Analysis for model comparison showed that the
combined-PI predictor added significant information to tumor
size and TP53 mutations (analysis of deviance p=0.04; Akaike’s
Information Criterion (AIC) for model with and without
combined-PI =191.8 and 194.01, respectively; Table S2). We
used AIC in a hybrid stepwise strategy to build a final prognostic
model where the combined-PI and tumor size were left as
covariates and ER status as stratification variable in a Cox
regression model (AIC: 191.46; Table S2. Likelihood ratio test
p=0.002; Table 6). The final model exhibited proportional
hazards (p=0.85; Table S2).
The combined-PI risk predictor had the most significant effect
in the final multivariate model (p=0.004). The HR for the
combined-PI high-risk group was 3.34 (95% CI 1.49—7.51)
compared with the low risk group. The partial PVE was calculated
to indicate relative importance of the individual predictor in the
multivariate setting: The combined-PI risk predictor captured
11.3% of the variability compared with 5% captured by tumor
size. The C-index (C=0.71) indicated satisfactory predictive
discrimination ability for the final multivariate model.
Breast cancer specific death as clinical endpoint
The proposed framework was also applied with breast cancer
specific death as the clinical endpoint and the results are
presented in Figure 2-4, 6. The predicted PI scores of the risk
of dying from breast cancer by individual gene sets are
summarized in the box plot in Figure 2B. The tuning parameters
chosen by leave-one-out cross-validation are shown in Figure S3.
The correlation structure indicates concordant predictions made
by different gene sets (Figure 4B). Overall, the gene set SD had
the weakest correlation to the other gene sets. Hierarchical
clustering of the test set patients based on the predicted PI matrix
defined to two risk clusters (Figure 3C) with distinct clinical
characteristics and associated with significantly different survival
probabilities (p=0.014); see Figure 3D. Risk scores were
combined as previously described into one risk score by
projecting the PIs onto the first principal component
(Figure 6C), in which 73% of the total variance was captured.
The continuous score was further dichotomized into high risk and
low risk using the median of the PC1 score. The difference in the
Table 5. Clinical and molecular characteristics of the two risk
groups from hierarchical clustering of the test patients based
on the predicted PI matrix.
Low risk High risk
Number of patients 44 33
Number of events (Recurr.) 14 20
Median survival (month) - 53.9
LumA (%) 29/38 (76) 9/38 (24)
Basal (%) 5/13 (39) 8/13 (61)
ER+ (%) 33/45 (73) 12/45 (27)
PR+ (%) 32/51 (63) 19/51 (37)
TP53 mutated (%) 2/20 (10) 18/20 (90)
Grade 1 (%) 6/6 (100) 0/6 (0)
doi:10.1371/journal.pone.0017845.t005
Figure 4. Correlation structure of predicted PIs from gene sets
with convergence in model-building stage. Heatmap of Spearman
correlation matrix of predicted PIs for corresponding survival endpoint
from individual gene sets. (A) For systemic recurrence, nine gene sets
that reached convergence during modeling building are displayed. (B)
For BC specific death, ten gene sets that reached convergence during
modeling building are displayed. Figure A and B share the same color
legend.
doi:10.1371/journal.pone.0017845.g004
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was confirmed by the logrank test (p=0.001; Kaplan-Meier plot
in Figure 6D). For comparison, the univariate performances of
individual gene sets for dichotomous prediction and clinical
parameters as well as AOL are shown in Figure S4 and Methods
S1. The combined-PI risk predictor for breast cancer specific
death was the most significant among all the tested predictors in
the univariate setting (likelihood ratio test p=0.001) with the
second largest HR 3.36 (95% CI 1.5—7.4), following TP53
mutation status (HR 3.46 with 95% CI 1.7—7.2; Figure S4B).
Furthermore, it had the second largest C-index (C=0.77)
following TP53 (C=0.8; Figure S4A) and it was also highly
ranked by PVE (12.4%) and deviance (10.2) following node status
(PVE=12.5%, Deviance=10.3; Figure S4A). The combined-PI
risk predictor was the most significant predictor (p=0.005;
Methods S1) with HR 4.62 (95% CI 1.58—13.55) in a
multivariate Cox model containing combined-PI risk, TP53
mutation status (HR=2.6, 95% CI 0.86—7.78), tumor size and
node status, stratified by ER status (See Methods S1 for the AIC
stepwise model selection). The correlation between the com-
bined-PI predictor and TP53 mutation status appeared to be
significant (odds ratio 33.9 with 95% CI 4.8—1490.4, Fisher’s
Exact test p,0.001; Methods S1) and the combined-PI added
significant information to TP53, tumor size and node status
(analysis of deviance p=0.035; AIC for model with and without
combined-PI =149.96 and 152.41, respectively; Methods S1).
Figure 5. Systemic recurrence: Kaplan-Meier plot of the PI-risk groups for each of the individual gene sets. The Kaplan-Meier curves
and the associated logrank p values for dichotomized PI-risk groups from each of the 9 converged gene-set models.
doi:10.1371/journal.pone.0017845.g005
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proportional hazards assumption was met for the reported
models (Methods S1).
Assess robustness of the combined-PI model
To test the robustness of the proposed procedure, we performed
the analyses by switching the test and training sets. To gain
computational efficiency, we applied 10-fold CV instead of
LOOCV during the model training procedure for each of the
gene sets. We obtained similar results for prediction of BC specific
death (Figure S5E–H). The combined-PI predictor and TP53
mutation status was strongly correlated (odds ratio 11.2 with 95%
CI 4.0—36.8, Fisher’s Exact test p,0.001). For prediction of
systemic recurrence, only three out of the eleven tested gene sets
Figure 6. Systemic recurrence: PCA of predicted PIs from converged gene sets and performance of the resulting groups from PC1.
Results for systemic recurrence are in (A-B); for BC specific death in (C-D). (A) Scatter plot of predicted PIs from 9 converged gene-set models on the
space of the top two leading PCs. Black circles indicate censored observations; red dots indicate patients with relapse. (B) The Kaplan-Meier curves for
high and low risk groups are significantly different (x
2=8.76, df=1, p=0.003). (C) Scatter plot of predicted PIs from 10 converged gene-set models on
the space of the top two leading PCs. Black circles indicate censored observations; red dots indicate patients with BC specific death; brown stars
indicate death from other reasons. (D) The Kaplan-Meier curves for high and low risk groups are significantly different (x
2=10.26, df=1, p=0.001).
doi:10.1371/journal.pone.0017845.g006
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compromised combined-PI risk predictor built from insufficient
signals (Figure S5A–D).
Furthermore, we also checked the stability of the combined-PI
prediction by correlating the predicted combined-PIs on the test
set from one analysis with the combined-PIs on the training set
from the switched analysis. The continuous PCA combined-PI
scores were used instead of dichotomizing on PC1. We performed
this screening for the prediction of BC specific death, and observed
moderate correlations of the combined-PIs on the MicMa set
(0.48) as well as on the Ull set (0.63). This indicates clearly that
there is a fair correlation between the combined-PIs when trained
on different data sets, but also that there is substantial variation.
Discussion
High-throughput genome profiling for genetic marker discovery
is widely applied in the field of genomic and personalized
medicine. For example, a gene signature characterizes certain
biological aspects and/or may be used to predict disease outcome
by mathematically combining the expression values of a set of
genes. The methods generating the combined expression pattern
of the biomarkers differ from study to study. A gene signature
therefore consists of a group of gene identities together with a
distinct classifier or a predictor to predict disease outcome.
In the present work, we applied Cox regression to reconstruct a
classifier from the same set of original genes as a number of
published gene signatures. Only the associated gene identities from
the original signature are retained, while the classifiers themselves
are derived on the basis of the same modeling procedure and the
same tumor data set. As a consequence, the resulting gene
signatures are derived on the basis of the same clinical endpoint
(systemic relapse or breast cancer specific death). The gene sets in
our study were pre-selected based on prior knowledge in breast
cancer. We are interested in survival prediction by the collective
expression pattern of the whole gene set without additional gene
selection. Furthermore, since the number of features (genes)
outnumbers the number of samples in the training set, p . N, for
most of the gene sets of interest, direct estimation of the coefficients
using standard Cox regression is unfeasible. Even for those gene
sets with p , N, we still have p large enough to render the
coefficient estimates highly unstable and thus of doubtful value for
prediction. Accordingly, we perform parameter estimation using a
penalized partial likelihood criterion [17] that forces the solution
to the estimation problem to have small L2-norm. Using an L2
penalty trades a little bias for a larger reduction in variance to
reduce the prediction error on a new data set. This is the so-called
‘‘bias and variance tradeoff’’ [18]. Cox-ridge regression has been
shown to be an effective model in survival prediction using gene
expression data [19,20]. There is no actual variable selection
involved; while genes are generally down weighted, all the genes
included in the Cox model will be present in the final model.
We observed that two of the pre-selected gene sets failed for
survival prediction at the model training stage: gene set LM for
Table 6. PCA-combined PI risk predictor in univariate and multivariate Cox regression.
Univariate Multivariate
Covariate p PVE* Deviance C
1 HR [95% CI] p Partial PVE C
Combined-PI risk (overall effect) 0.003 0.106 8.611 0.746 11.3%
High (vs Low) 3.34 [1.49, 7.51] 0.004
AOL risk 0.131 0.033 2.283 0.734
TP53 0.006 0.092 7.47 0.759
Tumor size (overall effect) 0.009 0.117 9.358 0.706 5%
pT2 (vs pT1) 2.59 [0.86, 7.81] 0.091
pT3-pT4 (vs pT1) 2.97 [0.85, 10.42] 0.089
Stage 0.058 0.111 7.501 0.698
Node 0.107 0.076 6.090 0.605
ER 0.634 0.003 0.227 0.403
Histological grade 0.372 0.025 1.979 0.480
RS 0.028 0.061 4.827 0.686
AMST 0.148 0.027 2.092 0.630
ROT 0.058 0.046 3.591 0.686
Grade 0.013 0.077 6.174 0.712
Robust 0.02 0.068 5.391 0.703
Hypoxia 0.303 0.014 1.06 0.626
Stem 0.734 0.001 0.115 0.535
Intrinsic 0.508 0.006 0.437 0.538
WR 0.079 0.039 3.093 0.640
Multivariate model Risk = Combined-PI + Tumor Size + strata(ER) 0.002 0.19 (R
2) 0.705
For overall effect of the predictor in univariate Cox regression, Likelihood ratio test p value was reported. For individual levels within the predictor, Wald test p value was
reported.
*PVE: proportion of variation explained in the outcome variable.
1C: concordance index.
doi:10.1371/journal.pone.0017845.t006
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relapse. The reason for their poor performance is likely related to
the lack of comparability of the data and methods used to
construct the original gene signatures and those used to construct
ours. Gene set LM contains 54 genes that mediate risk of breast
cancer metastasis to lung [7]. The original risk index for lung
Figure 7. Univariate comparison of predictors for systemic recurrence. Comparison of combined-PI risk predictor with clinical parameters
and individual gene-set predictors using univariate Cox model. (A) Y axis indicates C-index associated with individual predictor and X axis indicates
the p values (on minus log10 scale) from likelihood ratio test in univariate Cox model. C-index =0.5 and the significant level: a=0.05 for the
likelihood ratio test are indicated by the dotted line. The size and the color of the bubble indicate the PVE and the deviance in univariate Cox model,
respectively. The combined-PI risk predictor had the most significant marginal effect for predicting systemic recurrence (p=0.003). It was associated
with the second highest C-index score (C=0.75) following TP53 mutation status (C=0.76). It had the second highest deviance (8.61) following tumor
size (9.36), and the combined-PI predictor alone explained 10.6% of the variability as indicated by PVE, following tumor size (11.7%) and stage (11.1%)
(B) X axis indicates HR from the univariate Cox model and the 95% CIs are shown along with the point estimates. ‘‘LR test’’ stands for likelihood ratio
test. Insignificant predictors (likelihood ratio test p.0.05) are grayed out. To keep the results interpretable, only predictors with two levels are
compared. The combined-PI risk predictor had the 2
nd largest HR (2.82 with 95% CI 1.37—5.80) following TP53 mutation status (2.87 with 95% CI
1.42—5.83).
doi:10.1371/journal.pone.0017845.g007
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values weighted by their estimated Cox regression parameters.
The essential biological information captured in the original Minn
et. al dataset [7] was absent from the cohorts studied in the present
work, which contain mainly early-stage breast cancers. Given the
comparable methods in classifier construction, we believe the
biological incomparability of data sources used for model building
led to the poor performance of gene set LM in our study. Likewise,
the gene set SD might not have been expected to perform well due
to the intrinsic biological differences in the training sets used for
the present study and the original study, where microdissected
stroma from breast cancer specimens were used to identified these
26 stroma-derived prognostic genes [21]. Not all gene sets that
were left for the model evaluation achieved significant survival
prediction in the studied test set (Figure 5 and Table 6). The inter-
cohort heterogeneity most likely played a role. The studied
training and test set showed borderline significantly different
survival probabilities for the survival endpoints (systemic relapse
p=0.0765; breast-cancer specific death p=0.0564; Figure S6).
Unless there exists a ‘‘gold-standard’’ dataset representing
perfectly the underlying population for breast cancer, dealing
with the heterogeneity feature is inevitable. The proposed
framework demonstrates a straightforward yet effective approach
to improve the survival prediction power by integrating multiple
gene set predictors.
Interestingly the combined-PI risk predictor correlates with but
provides additional information to TP53 mutation status. TP53
mutation status has been shown to be one of the strongest single
molecular prognostic markers in breast cancer. It is known as a key
molecule involved in different pathways important in cancer. It is a
molecular marker important to compare with other prognostic
markers to gain insights about the underlying biology. It is a prime
example of a single molecule not function alone, but rather
involving many players in various networks. Restoring TP53
activity is a potential therapeutic strategy [22].
The results indicated that to some extent the generalization
from MicMa set to Ull set was better than that from Ull to MicMa.
We suspect the main reason may be the reduction of the training
set sample size from 123 in the MicMa cohort to 80 in the Ull
cohort. Since the training step is prone to over-fitting due to the
large number of genes from which the models may be fitted, the
ability to fit a reliable model strongly depends on having a
sufficient sample size.
As a potential extension of the framework of mining large
collection of gene sets for survival prediction, an optional filter step
could be added prior to the analysis to eliminate gene sets that are
not significantly related to survival or not enriched in the training
set. Our analysis framework does not restrain to the gene sets from
gene signatures, as this is one of the many ways to provide input to
the ‘‘combining power procedure’’.
In conclusion, our proposed framework for improving survival
prediction contains three analytical modules: (1) gene signature
(gene-set prognostic model) construction, (2) dimension reduction
and (3) risk prediction. Each module could be fine tuned or
modified depending on the data under study. Our study showed
that by aggregating the predictive strength from multiple gene sets
we can improve the outcome prediction in breast cancer, and it
can be broadly applicable to breast cancer survival risk assessment.
Materials and Methods
Ethics statement
The studies included in the project were approved by the
Regional Ethical Committee (REK: S97103 for MicMa and REK:
200401129-1 for Ull). All samples were obtained with written
informed consent approved by the ethical committee.
Tumor samples and patients
The training set (MicMa) comprise published gene expression
and clinical data on 123 human breast cancer cases, mainly stage I
and II [11]. Patients were treated for localized breast cancer and
included between 1995 to 1998 [23]. The prognostic model for
relapse was trained using 118 patients with available endpoint
status. All the 123 patients were available for training the
prognostic model for breast cancer specific death. The test set
(Ull) mainly consisted of early stage breast cancers from which
gene expression and clinical data were available [16]. Patient
samples were sequentially collected from 1990 to 1994. In this data
set, together with eighty tumor cases a normal breast tissue sample
coded as ‘‘DNR_N_AO100’’ was included as control. Descriptive
aspects of the training and test sets are given in Table S3. More
details are provided in Methods S1.
Microarray
Both the training set (MicMa) and test set (Ull) were obtained
using the Stanford 43k cDNA microarrays. Using the protocols
described in Methods S1, total RNA was isolated, amplified,
labeled and hybridized to arrays containing around 42,000
features representing 23169 unique cluster IDs (UniGene Build
Number 215) produced at the Stanford Functional Genomics
Facility (http://www.microarray.org/sfgf/jsp/home.jsp). All pro-
cedures are available at Stanford Genomics Breast Cancer
Consortium Portal (http://genome-www.stanford.edu/breast_
cancer/) for the MicMa set and at the referred web site (http://
www.stanford.edu/group/sjeffreylab/) for the Ull set. All data is
MIAME compliant. Raw data for MicMa set has been deposited
in the NCBI’s Gene Expression Omnibus database (GEO; http://
www.ncbi.nlm.nih.gov/geo/) with accession number GSE3985.
Both datasets are accessible through Stanford Microarray
Database (SMD; for the MicMa set: http://smd.stanford.edu/
cgi-bin/publication/viewPublication.pl?pub_no=833; for the Ull
set: http://smd.stanford.edu/cgi-bin/publication/viewPublication.
pl?pub_no=629).
Preprocessing
For the MicMa set, normalized (loess with print tip
stratification) log2-transformed gene expression ratios were
retrieved from SMD (http://smd.stanford.edu/), filtered for spot
intensity over background at least 1.5 in both sample and
reference, and finally, filtered for those genes that fulfilled the
spot filter criteria in at least 85% of the experiments. For the Ull
set, probes were filtered for spot quality and included in the
analysis if the pixels within a spot showed a regression correlation
of at least 0.6 or if the signal intensity of both sample and
reference were at least 1.5 over background; data were further
normalized by the default total Intensity Normalization in SMD
(http://smd.stanford.edu/help/results_normalization.shtml). For
both MicMa and Ull, k-nearest neighbor (KNN) imputation [24]
with k=10 was applied to impute missing values in the filtered
expression dataset.
Gene sets
An overview of the 11 published gene sets studied in this report
are listed in Table 1. The abbreviated coding for the individual
gene sets are used instead of the full name throughout this paper.
The annotation files for the gene sets were downloaded from the
web sites indicated in the original publications or were requested
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presented in the Methods S1.
Adjuvant! Online model
Adjuvant! [25] (https://www.adjuvantonline.com) uses patient
age, comorbidity level, ER status, tumor grade, tumor size and
number of positive lymph nodes to predict 10-year risk for breast
cancer mortality. It also predicts the benefit of adjuvant therapy
for women with early-stage breast cancer. A description of the
Adjuvant! Online model and the details for computing risk scores
of the test patients can be found in Methods S1. Low risk is defined
in this paper as lower than 10% 10-year risk of breast cancer
mortality. A total of 72 patients in the Ull data set with suitable
characteristics for Adjuvant! Model were entered into the
comparison study.
Molecular subtype assignment
Tumors were assigned to a subtype using Pearson correlation to
the expression centroids as previously described [16,26].
Cross-platform gene identity mapping
Most of the gene sets in the study were developed from
microarray platforms different from Stanford 43k cDNA array (see
Table 1). For gene sets developed from Stanford 43k cDNA arrays,
clone IDs were used as the ‘‘linker’’ to link the gene identifiers in
the gene set to cDNA. For gene sets developed from different
platforms, gene identifiers in the gene set were mapped to the
cDNA clones using the following linkers: UniGene, gene symbol
and gene alias, where UniGene had the highest priority while gene
alias had the lowest priority. When matches occurred by using
multiple linkers, we took the matches from the highest ranked
linker. Furthermore, we collapsed the matched clones representing
the same gene by their mean expression value (Figure 1A).
Annotations for Stanford 43k cDNA array were retrieved from
SMD SOURCE (http://smd.stanford.edu/cgi-bin/source/sour
ceSearch) under UniGene Build Number 215. And annotations
for the individual gene sets were retrieved either from manufacture
chip annotation files or from SMD.
Penalized Cox regression for survival prediction based on
individual gene sets
We assume that at any given time, a breast cancer patient has a
certain risk of experiencing a specific event, which in our case is
either relapse after primary surgery or breast cancer related death.
We furthermore assume that for a number of patients we have
measured the time to this event. Patients that experience none of
these events for the duration of the study are labeled as censored.
For such patients, the recorded time is simply the last point of
observation and carries a different interpretation than a time to an
event. To associate the risk of an event to observed features, we
consider a Cox’s proportional hazards model (Cox model) with the
expression of selected genes as the covariates. Suppose that for a
patient we have observed a total of p expression values
X~(X1,X2,:::,Xp)’. In principle, we may model the risk of
relapse/death as a function of all measured expression values, as
in the Cox model h(tDX)~h0(t)exp(b’X), where the interpretation
is that the instantaneous risk (also known as the hazard)o f
experiencing the event at time t is a product of two functions, the
first depending only on the time point (and not on the particular
patient at hand), and the second depending only on the expression
values of the patient (and not on the time point). In a Cox model,
the relative hazard between two individuals with expression
vectors X1 and X2respectively is expressed by the quantity
h(tDX1)
h(tDX2)
~exp(b’(X1{X2)):
Accordingly, even though the hazard fluctuates over time for
any one individual, the relative hazard between individuals is
constant over time. Let P(X)~(xi1,xi2,:::,xim)’ denote a subselec-
tion of genes (variables) from the complete list of p genes.
Considering the risk of relapse/death as a function of the selected
genes only, we obtain the Cox model hP(tDX)~h0(t)exp(b’P(X)).
In this paper, we want to model risk of relapse/death as a function
of R=11 gene sets of individual sizes m1,:::,mR, each correspond-
ing to a particular subselection of genes. Thus, we consider the
Cox models
hj(tDX)~h0(t)exp b’ jPj(X)

ð1Þ
where j=1,2,…,R indexes the gene sets, Pj(X) is the selected genes
(variables) in the jth gene set, bj~(bj,1,bj,2,:::,bj,mj) is the vector of
coefficients (weights) associated with the genes in the jth gene set,
and h0(t) is the (common) baseline hazard function. Since the
response of interest is a possibly censored survival time, for a given
gene set, a Cox proportional hazards model was used to describe
the risk of a patient experiencing an event in response to
expression of gene covariates. The expression values for each gene
were mean centered and scaled to unit standard deviation in both
the training and the test datasets. All Cox models in the gene
signature construction part of the analysis were fitted using an L2-
penalized partial Cox likelihood, whereas the Cox model in the
multivariate comparison was fitted using the ordinary partial Cox
likelihood. To determine the penalty parameter, we applied the
leave-one-out cross validation procedure proposed by Verweij and
van Houwelingen [17] (See Methods S1).
A total of 118 MicMa patients with available information on
systemic recurrence status were used to develop a prediction
model using Cox-ridge regression for a gene set. For the j’th gene
set (j=1, …, 11), the optimal gene-set specific tuning parameter
^ l ljwas found by the leave-one-out cross validation procedure [17]
using the training set; we then estimated the coefficient vector ^ b bj
associated with individual genes in gene set j by the Cox-ridge
model (1) (Figure 1A). The predicted prognostic index for the jth
gene set and the ith patient in the test data set was calculated as
PIij~^ b b’jPj(Xi
test) which is sum of weighted gene expression of the
test patient i (Figure 1A). The weights ^ b bj for individual genes in the
jth gene set were the corresponding estimated coefficients from the
training set using the Cox-ridge model (1) (Figure 1A). See
Methods S1 for details.
Prediction performance evaluation for individual gene
set
Spearman correlations were used to show the concordance
structure for risk prediction among the gene sets. The change in
deviance (DD) is an indicator of predictive performance of a model
obtained from a training dataset on a novel test dataset and is
given by DD~{2(lfull{lnull) where lfull is the optimal log-
likelihood with all the genes in the gene set included, and lnull is the
optimal log-likelihood with no genes included. The continuous PI
scores were dichotomized into high- and low-risk groups using
zero as cutoff, where a positive PI score indicates high risk. The
resulting PI risk groups for individual gene set were tested in a
univariate Cox model and the difference of the Kaplan-Meier
survival curves of the groups were also tested by logrank test.
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As a graphical illustration of the relationship among the gene
sets, the predicted PIs for all patients in the test set (Ull) using each
of the gene sets were clustered using hierarchical clustering with
Spearman correlation and average distance. The Kaplan-Meier
survival curves were plotted for the resulting groups and the
differences in clinical indications among the clusters were tested by
a logrank test.
Dimension reduction by principal components analysis
Principal components analysis (PCA) was used to project the PIs
from each of the individual gene sets onto a lower dimensional
space (Figure 1B). The values off the first principal component
were used as the combined risk scores, and further dichotomized
by median cut, where a patient with a score on PC1 higher than
median values on PC1 was considered to be high risk. A logrank
test was carried out to assess the significance of the differences in
survival probabilities associated with resulting dichotomous risk
groups (Figure 1B). The method of choice was PCA based on the
covariance matrix since we expected PIs with higher variance to
carry more information than PIs with less variance. In analyses of
relapse, however, this ended up dominated by Hypoxia although
this correlated little with other PIs, and was therefore replaced by
PCA based on the correlation matrix.
Univariate comparison of predictors
Univariate Cox models were used to compare the effects of the
combined-PI risk predictor, individual gene signatures (dichotomized
by splitting at 0), clinical parameters (Tumor size and Histological
grade, TP53, Node status, ER status and Stage), as well as the
Adjuvant! Online model. A likelihood ratio test was used to assess the
significance of the overall effect of a predictor in the univariate
models. In addition, deviance was used to check the goodness of the
model fit. The marginal contribution by a single predictor in the
univariate setting was evaluated using the proportion of variation
explained in the outcome variable (PVE) [27]. PVE R2
M,
comparable with the R
2 in regression modeling is an indicator
that quantifies the importance of covariates in the Cox model.
The Hazard Ratio (HR) was used as an accuracy measure for the
risk group prediction for different predictors. In the univariate
setting, HR is a summary of the risk difference between patient
groups defined by the predictor. To keep the results interpretable
and comparable, we presented the HRs for the predictors with two
risk groups (excluded Tumor size, Histological grade, Node status
and Stage). The larger the HR, the better is the discrimination
between the groups of the patients, such as low- and high-risk.
The concordance index (C-index) [28], an analogy to area under the
receiver operating characteristic (ROC) curve in survival analysis,
was computed to assess the predictive discrimination ability of each
of the predictors in the corresponding univariate Cox model
(Method S1). It measures the probability of concordance between
the predicted and observed responses in terms of lengths of time to
event of any two patients. The larger the C-index, the better is the
predictability of a survival model. A value of 0.5 indicates no
predictive discrimination and a value of 1 indicates perfect
separation of patients with different outcomes [28].
Multivariate comparison of predictors
The significantpredictorsintheunivariate analysiswereincluded
in a multivariate Cox model. Model selection was carried out using
Akaike’s Information Criterion (AIC) [29] and analysis of deviance.
The relative importance of a covariate in a multivariate Cox model
was measured by the partial PVE, which was calculated as the
difference between R2
M for the full model and R2
M for a model with
a factor of interest excluded. See Methods S1 for details.
Software
All analyses were performed in R (version 2.11.1), which is
available at http://cran.r-project.org/. The R package ‘‘penal-
ized’’ [30] was to perform penalized Cox regression. R code for
the procedures described in this paper are available from the
correspondence author.
Supporting Information
Figure S1 Systemic recurrence: Cross-validated likeli-
hood profile on l grid. The dotted line indicates the location of
the optimal l value lopt for each gene set. RS: 338; SD: Inf; LM:
Inf; AMST: 227; ROT: 1029; Grade: 3580; Robust: 1705;
Hypoxia: 392; Stem: 3623; Intrinsic: 1576; WR: 11261. Modeling
gene set SD and LM did not reach convergence by the specified
criteria in the study.
(TIF)
Figure S2 Systemic recurrence: Hierarchical clustering
of estimated PIs for systemic recurrence on training set
and the resulting risk clusters in a Kaplan-Meier plot. (A)
Heatmap of estimated PIs on training set for systemic recurrence
from each gene sets. Rows are notations for the gene sets. Columns
are annotation for the patients; data outside of 1% quantile were
trimmed. ‘‘Average’’ linkage based on Spearman correlation was
used to construct the dendrograms. Two risk clusters I and II, were
observed from the hierarchical clustering with distinct clinical
characteristics: a total of 30 out of 49 Luminal A tumors (61%)
were clustered in the low risk group, and 19 luminal A tumors
(39%) were found in the high risk group. (B) The Kaplan-Meier
curves for cluster I and cluster II. A significant separation between
the two clusters was observed (x2=49.7, df=1, p,0.001).
(TIF)
Figure S3 BC specific death: Cross-validated likelihood
profile on l grid. The purple dotted line indicates the location of
the optimal l value lopt for each gene set. RS: 343; SD: 249; LM:
Inf; AMST: 230; ROT: 379; Grade: 1337; Robust: 898; Hypoxia:
1823; Stem: 3866; Intrinsic: 1639; WR: 8317. Modeling gene set
LM did not reach convergence by the specified criteria in the study.
(TIF)
Figure S4 Univariate comparison of predictors for BC
specific death. (A) Y axis indicates C-index associated with
individual predictor and X axis indicates the p values (on minus
log10 scale) from likelihood ratio test in univariate Cox model. C-
index = 0.5 and the significant level: a = 0.05 for the likelihood
ratio test are indicated by the dotted line. The size and color of the
bubble indicates the PVE and deviance in univariate Cox model,
respectively. The combined-PI risk predictor for BC specific death
was the most significant one among all the tested predictors
(likelihood ratio test p = 0.001). It had the second largest C-index
(C = 0.77) following TP53 (C = 0.8). And it was also highly
ranked by PVE (12.4%) and deviance (10.2) following node status
(PVE = 12.5%, Deviance = 10.3). (B) X axis indicates HR from
the univariate Cox model and the 95% CIs are shown along with
the point estimates. ‘‘LR test’’ stands for likelihood ratio test.
Insignificant predictors (likelihood ratio test p . 0.05) are grayed
out. The combined-PI risk predictor had the second largest HR
3.36 (95% CI 1.5—7.4), following TP53 mutation status (HR 3.46
with 95% CI 1.7—7.2).
(TIF)
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as training set and MicMa as test set. Results for systemic
recurrence are in (A-D); for BC specific death in (E-H). (A)
Boxplot of predicted PI for systemic recurrence. Only three out of
eleven gene sets had converged model in model training stage. (B)
Spearman correlation structure among gene sets with conver-
gence. (C) Projection of the predicted PIs on space formed by
PC1 (captured 81% variability) and PC2. (D) Kaplan-Meier
curves associated with the two risk groups by median-cut of PC1
value (logrank p =0 . 1 9 1 ) .( E) Boxplot of predicted PI for BC
specific death. (F) Spearman correlation structure among gene
sets with convergence. (G) Projection of the predicted PIs on
space formed by PC1 (captured 65% variability) and PC2. (H)
Kaplan-Meier curves associated with the two risk groups by
median-cut of PC1 value (logrank p =0 . 0 2 8 ) .
(TIF)
Figure S6 Survival curves for training set (MicMa) and
test set (Ull). The logrank test showed that the training cohort
and test cohort had borderline significant survival curves for the
survival endpoint.
(TIF)
Table S1 Results summary of PCA on predicted PIs for
systemic recurrence from 9 converged gene sets.
(PDF)
Table S2 Results summary of univariate and multivar-
iate analysis of combined PI-risk predictor for systemic
recurrence.
(PDF)
Table S3 Molecular and clinicopathological character-
istics of the tumor material in MicMa and Ull datasets.
(PDF)
Methods S1 Supplementary methods, results, notes,
and references.
(PDF)
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